Get in Touch

Mitigating payer uncertainties around an oncology OD

  • Price Optimisation
P4A helped us devise a set of practical solutions that addressed payer uncertainties around our product.
Global Market Access Director

Client Challenge

Developing an innovative contracting framework for use by affiliates across Europe.

A large Pharma company launching an oncology agent that received conditional EMA approval based on Phase 2 data.

There were a lack of payer relevant outcomes in evidence package (OS and PFS) and the epidemiology were key uncertainties for payers.

P4A Solution

Innovative contracting is not the panacea for all uncertainties; payers only engage if a solution can be easily implemented with a win-win outcome.

P4A implemented the following recommendations:
  • Developed a solution blueprint
  • Engaged and refined this blueprint with payers
  • Developed framework for organizational use

The Successful Outcome​

  • Developed a suite of value based contracting strategies
  • Identified that value based contracting is not a default option. Instead staggered intro should be explored in the opening offer
  • Designed a streamlined RWE plan to address both regulator and payer needs whilst minimising burden on HCPs & patients

Need more details?

Do you want to learn more about the successful outcome for this case study? Are you interested in P4A Services or just want to say Hi?

get in touch

Explore other case studies

Understand evidence requirements beyond clinical trial data for launching an orphan drug in Türkiye & the GCC

  • Access Strategy

Optimising the PRMA potential of an orphan oncology asset in EU4 + UK and Japan

  • Access Strategy, Price Optimisation
p4a-logo-small-retina-white

We are award winning global experts in access for orphan drugs and Cell and Gene Therapies.

Twitter Instagram Youtube Linkedin

About

Services

Insights

Case Studies

Contact

  • Aramislaan 88,
  • 6213BV Maastricht, Netherlands
  • +31 6 55 88 71 96
  • contact@partners4access.com

P4A Services

For all access and Rare Disease related overview enquiries